Evidence map›Paper›PMID 37812356›Full record

ArticleMolecular biology reports2023

The synergistic effects of betanin and radiotherapy in a prostate cancer cell line: an in vitro study.

Soheila Montazersaheb, Sevda Jafari, Mutlu Dilsiz Aytemir, Elham Ahmadian, Mohammadreza Ardalan, Murat Zor, Aygun Nasibova, Amirabbas Monirifar, Sara Aghdasi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Soheila Montazersaheb *Molecular Medicine Research Center, Tabriz University of Medical Sciences, Tabriz, 5166614731, Iran.
Sevda Jafari *Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mutlu Dilsiz AytemirFaculty of Pharmacy, Department of Pharmaceutical Chemistry, Hacettepe University, Sıhhiye, Ankara, 06100, Turkey.
Elham AhmadianKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ahmadian.elham@yahoo.com.ORCID http://orcid.org/0000-0002-7230-0489
Mohammadreza ArdalanKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ardalan34@yahoo.com.ORCID http://orcid.org/0000-0002-6851-5460
Murat ZorDepartment of Pharmacognosy, Faculty of Pharmacy, Fenerbahçe University, Ataşehir, İstanbul, Turkey.
Aygun NasibovaInstitute of Radiation Problems, Ministry of Science and Education Republic of Azerbaijan, Baku, AZ1143, Azerbaijan.
Amirabbas MonirifarKidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sara AghdasiGraduated from the faculty of veterinary medicine, Urmia University, Urmia, Iran.
Tabriz University of Medical Sciences · IRBaku State University · AZFenerbahçe University · TRIzmir Kâtip Çelebi University · TRUrmia University · IR

Funding

Tabriz University of Medical Sciences IR.TBZMED.VCR.REC.1401.102
6 · The paper itself

Abstract

backgroundProstate cancer is among the most common cancers in men with an increasing incidence rate. Radiation therapy (RT) is a therapeutic strategy for the management of prostate cancer after surgery; nonetheless, it has different side effects on neighboring healthy cells/tissues. Moreover, radioresistance has been an increasing phenomenon in the recent years. Therefore, there is an urgent need for the introduction of a safe and effective radiosensitizing agent. Accordingly, the recent trend in the development of novel drugs is accompanied by a push toward natural compounds. Our study evaluated the effects of betanin combined with RT as a potential radiosensitizing agent in the PC-3 cell line. METHODS AND

resultsMTT assay was utilized to determine the growth inhibitory impact of betanin. The possible synergistic effect was evaluated with CompuSyn software upon Trypan blue exclusion test. Apoptosis-related gene expression was evaluated via Real-time PCR and the protein expression of P21 was determined using western blotting. A synergistic anticancer effect with an optimal combination index of 0.61 was achieved by treating PC-3 cells with betanin and RT. The results pointed out that betanin synergistically triggered RT-mediated apoptosis and cell cycle arrest through modulating gene and protein expression in comparison with each of the monotherapies.

conclusionThese findings shed light on the synergistic antitumor effect of betanin and RT in prostate cancer, indicating the potential use of betanin as a radiosensitizer agent.

Indexed as

Prostatic NeoplasmsRadiation-Sensitizing AgentsApoptosisBetacyaninsCell Line, TumorHumansMaleBetacyaninsbetaninRadiation-Sensitizing AgentsBetaninProstate cancerRadiotherapy

Identifiers

PMID37812356
OpenAlexW4387439128

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.